Oskar Bordeaux
Not a member yet
151482 research outputs found
Sort by
Twisted-Shaped Millimeter-Wave Hybrid Couplers in 150 nm GaN Technology for 5G Applications
No full textThis paper presents the first implementation of two innovative 90° hybrid couplers in Gallium Nitride (GaN) process designed for 5 G applications. In a very compact design, both couplers target low insertion loss (IL) and large fractional bandwidth (FBW1 dB) to replace conventional couplers. The first coupler exhibits minimum insertion loss of 0.44 dB at 22 GHz with a fractional bandwidth of 31%. The second coupler was optimized to reach a minimum insertion loss of 0.28 dB at 25.5 GHz with a fractional bandwidth of 29%, making it suitable for wideband applications. Both couplers perform with an output phase imbalance of 93∘±2∘. Both circuits were designed using 150 nm GaN on SiC GH15 technology from United Monolithic Semiconductors (UMS)
Technique de composite injecté dans la prise en charge d’un enfant atteint d’amélogénèse imparfaite
No full textL’amélogenèse imparfaite est une maladie génétique qui altère la qualité et/ou la quantité d’émail. Cette altération peut entraîner des conséquences fonctionnelles et esthétiques, impactant la qualité de vie des patients. La technique de composite injecté est une solution innovante et peu invasive, permettant de restaurer les dents affectées et d'améliorer le bien-être des patients. Dans cette thèse, nous présentons un cas clinique illustrant l’application de la technique de composite injecté.Amelogenesis imperfecta is a genetic disorder that affects the quality and/or quantity of enamel. This alteration can lead to functional and aesthetic consequences, impacting the patients' quality of life. The injected composite technique is an innovative and minimally invasive solution that helps restore affected teeth and improve patients' well-being. In this thesis, we present a clinical case to illustrate the application of the injected composite techniqu
Tutorial / Documentation on the RnmrQuant1D package - v1.10
No full textWiki pages gathered in a single document in PDF format regarding a Tutorial / Documentation on the RnmrQuant1D package dedicated to 1D proton NMR quantification, including peak fitting and based on external calibration using standard spectra.Tutorial / Documentation on the RnmrQuant1D package dedicated to 1D proton NMR quantification, including peak fitting and based on external calibration using standard spectra.Projet vin authenticité en RM
Investigation Into the Moisture Degradation Mechanism of Integrated Stacks Using New Moisture Sensor Design
No full textThis work presents a modified sensor design for moisture diffusion study of dielectrics within 3D integrated circuits. It allows to track, in addition to the electrical capacitance usually measured, the electrical resistance variations with aging. Based on electrical measurements and physical-chemical characterizations, we revealed valuable information on the moisture-induced failure mechanism for Low-k and ULK materials. We have put in evidence that electrical failures within the ULK material are possible under the effect of temperature and humidity. A discussion on the preferential path for Cu diffusion in ULK dielectric is also presented
Impact of Real-World Evidence Studies on the evolution of collaborative strategies between the pharmaceutical industry and patient associations
No full textCe travail s’intéresse à l’évolution des relations entre l’industrie pharmaceutique et les associations de patients, à travers le prisme des données de vie réelle. Il analyse comment ces données, de plus en plus mobilisées pour compléter les essais cliniques traditionnels, participent à transformer les pratiques de recherche et les équilibres institutionnels. Pour cela, il revient d’abord sur les fondements scientifiques des données en vie réelle, leur complémentarité avec les méthodes classiques, ainsi que les enjeux qu’elles soulèvent en matière de validité, de transparence et de représentativité. Il retrace ensuite l’histoire des mobilisations de patients, en mettant en lumière le rôle central de certaines pathologies comme le virus de l’immunodéficience humaine (VIH) dans la construction de nouveaux modèles d’engagement. Ce travail montre comment ces mobilisations ont permis aux associations de peser sur les politiques de santé, d’accéder aux instances de décision, et de contribuer à l’émergence d’un patient acteur. Enfin, à partir de cas concrets, il explore les formes actuelles de collaboration entre industriels et associations, rendues possibles ou renforcées par l’usage des données de vie réelle. Ces coopérations, parfois co-construites, redessinent les contours de la recherche médicale et posent les bases d’une gouvernance partagée. À travers cette analyse, le travail interroge les conditions d’une participation plus juste, informée et structurée des patients dans l’élaboration des stratégies thérapeutiques.This work focuses on the evolving relationship between the pharmaceutical industry and patient associations, through the lens of real-world data. It examines how these increasingly utilized data, complementing traditional clinical trials, contribute to transforming research practices and institutional dynamics. To this end, it first revisits the scientific foundations of real-world data, their complementarity with conventional methods, and the challenges they pose in terms of validity, transparency, and representativeness. It then traces the history of patient mobilizations, highlighting the central role of certain condition such as human immunodeficiency virus (HIV) in shaping new models of patient engagement. This work demonstrates how these movements have enabled associations to influence health policies, gain access to decision-making bodies, and foster the emergence of the patient as an active participant. Finally, drawing on concrete examples, it explores current forms of collaboration between pharmaceutical companies and patient associations, made possible or strengthened by the use of real-world data. These often co-constructed partnerships are reshaping the contours of medical research and laying the foundations for shared governance. Through this analysis, the work questions the conditions necessary for a more equitable, informed, and structured participation of patients in the development of therapeutic strategie
"Cadeira", de José Saramago : um exemplo de escrita e perspetiva revolucionárias
No full textThe short story 'Cadeira', published in the collection Objecto Quase [The Lives of Things] (1978), is part of a series of texts which, as well as illustrating the post-25 April break in José Saramago's career, evoke the challenges of the transition from dictatorship to democracy, drawing attention to this key moment in the country's history. The collapse of Salazar's dictatorship is evoked through unconventional narrative and stylistic strategies, allowing us to measure the impact of the Revolution on the work and to observe the revolution taking place in the writing itself. One of the most significant aspects of the subversion introduced by the text lies in the relearning of a critical, subversive and lucid vision as a bastion against the reduction of the human being to a mere object.O conto "Cadeira", publicado na coletânea Objecto Quase (1978), insere-se num conjunto de textos que, além de ilustrarem a rutura que intervém no pós-25 de Abril, na carreira de José Saramago, evocam os desafios da transição da ditadura para a democracia, chamando a atenção para este momento-chave da história do país. O desmoronamento da ditadura salazarista é nele evocado através de estratégias narrativas e estilísticas nada convencionais, permitindo medir o impacto da Revolução sobre a obra e observar a revolução que se dá na própria escrita. Um dos aspetos mais relevantes da subversão introduzida pelo texto reside na reaprendizagem de uma visão crítica, subversiva e lúcida enquanto baluarte contra a redução do ser humano a mero objeto
Programme Recherche - Action "Ensemble Sauvons la Forêt de Chantilly" - Les résultats scientifiques
No full textRestitution aux bénévoles d’Ensemble Sauvons la Forêt de Chantilly », Orry la Vill
Prescription of bDMARD/tsDMARD in patients with chronic inflammatory arthritis and a recent history of cancer
No full textObjectifs : les données sur l’utilisation des Médicaments antirhumatismaux synthétiques biologiques/ciblés modifiant le cours de la maladie [(B/tsDMARDs) (biologic/targeted Synthetic Disease-Modifying Antirheumatic Drugs)] chez les patients atteints de rhumatisme inflammatoire ayant un cancer récent sont limitées. L’objectif de cette étude était de rapporter leur prescription dans ce contexte spécifique. Méthodes : nous avons mené une étude observationnelle, utilisant l'entrepôt de données du centre hospitalier universitaire (CHU) de Bordeaux. Les patients atteints de polyarthrite rhumatoïde (PR), de spondyloarthrite (SpA) ou de rhumatisme psoriasique (Rpso) recevant un b/tsDMARD dans les cinq ans suivant un diagnostic de cancer ont été identifiés et les données ont été recueillies via un formulaire standardisé. Une analyse descriptive a été réalisée et les facteurs de changement de b/tsDMARD ont été évalués. Résultats : 135 patients (54,8% de femmes, âge moyen 61 ans) atteints de PR (n=86), de SpA (n=34) ou de Rpso (n=15) ont été inclus. Les b/tsDMARDs étaient interrompus au diagnostic de cancer, sauf pour 32 patients ayant un cancer cutané non mélanique in situ. Les anti-TNF étaient les thérapies les plus prescrites après le cancer (39,8%), suivies par le rituximab (24,3%). Le délai moyen entre le diagnostic du cancer et le début des b/tsDMARDs était de 14,7 mois. Parmi les patients dont le b/tsDMARD avait été interrompu au diagnostic du cancer, 39 (59%) ont repris la même classe thérapeutique et 27 (41%) ont changé après le cancer. Le changement de classe était plus fréquent chez les patients atteints de PR et chez ceux ayant une exposition plus courte aux b/tsDMARDs avant le cancer. Avec une médiane de suivi de 3,6 ans, 16 patients (15,5%) ont présenté une récidive de cancer. Conclusion : en l’absence de recommandations pour l’utilisation des b/tsDMARDs après un cancer récent, les rhumatologues tendent à privilégier les anti-TNF et le rituximab, avec une tendance à reprendre le b/tsDMARD précédemment interrompu. Les futures recommandations de l'alliance européenne des associations pour la rhumatologie (EULAR) influenceront certainement ces pratiques.Objectives: data on the use of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in patients with inflammatory arthritis and a recent history of cancer (<5 years) are limited. The objective of this study was to report their prescription in this specific context. Methods: we conducted an observational study using the health data warehouse of Bordeaux University Hospital. Patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), or psoriatic arthritis (PsA) receiving a b/tsDMARD within five years following a cancer diagnosis were identified, and data were collected via a standardized form. A descriptive analysis was conducted and factors influencing b/tsDMARD changes were assessed. Results: 135 patients (54.8% women, mean age 61 years) with RA (n=86), SpA (n=34), or PsA (n=15) were included. The b/tsDMARDs were discontinued at the time of cancer diagnosis, except for 32 patients with in situ non-melanoma skin cancer. TNF inhibitors were mostly prescribed after a recent cancer (39.8%), followed by rituximab (24.3%). Mean time between cancer diagnosis and initiation of b/tsDMARDs was 14.7 months. Among patients whose b/tsDMARDs had been discontinued at cancer diagnosis, 39 (59%) resumed the same therapeutic class, and 27 (41%) switched to a different class after cancer. The change was more frequent in RA patients and in patients with shorter exposure to b/tsDMARDs before cancer. With a median follow-up of 3.6 years, 16 patients (15.5%) experienced cancer recurrence. Conclusion: in the absence of guidelines for the use of b/tsDMARDs after a recent cancer, rheumatologists tend to favor TNF inhibitors and rituximab, and often resume the previously discontinued b/tsDMARD. Future european alliance of associations for rheumatology (EULAR) recommendations will likely influence such clinical practice